Please login to the form below

Not currently logged in
Email:
Password:

Biogen expands digital safety platform Assessa

The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting

BrainBiogen has expanded work on its digital safety platform, which helps monitor MS patients for signs of the rare and potentially fatel brain infection progressive multifocal leukoencephalopathy (PML).

The pilot programme, a collaboration with tech firm Ixico, will now include pharmacoviglance reporting to monitor patients for previously unreported adverse reactions.

The partners - who have been in a collaborative agreement since October 2015 - developed the Assessa system to provide neurologists with second opinion reading services if there is a suspicion of PML.

Giulio Cerroni, chief executive officer of Ixico, said: “We are delighted to announce the expansion of this pilot involving clinical experts in specialist MS centres and Biogen.

“The Assessa PML digital platform is intended to provide technology and speciality services to physcians involved in delivering care to people living with MS.”

Biogen has invested £1.5m in the project, which is currently being piloted in five EU countries.

Article by
Gemma Jones

11th August 2017

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics